|Year : 2015 | Volume
| Issue : 4 | Page : 147-148
Choose the right treatment for the right patients
Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung; Department of Ophthalmology, School of Medicine, National Yang-Ming University, Taipei, Taiwan
|Date of Web Publication||12-Apr-2017|
Department of Ophthalmology, Kaohsiung Veterans General Hospital, Number 386, Dazhong 1st Road, Zuoying District, Kaohsiung City 81362
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Sheu SJ. Choose the right treatment for the right patients. Taiwan J Ophthalmol 2015;5:147-8
Age-related macular degeneration (AMD) is one of the major causes of adult visual loss. During the past decade, the use of anti-vascular endothelial growth factor (anti-VEGF) agents for the treatment of neovascular eye disease has significantly changed the standard of care in retinal medicine and ophthalmology. Intravitreal injection of anti-VEGF drugs has since been widely employed clinically to mitigate disease progression and improve the visual outcomes of affected patients.
Although evidence-based data support the use of anti-VEGF pharmacotherapy in neovascular AMD, not every patient responds well to treatment. The factors contributing to the non-response include genetic factors, presence of polypoidal choroidal vasculop-athy, retinal angiomatous proliferation, presence of vitreoretinal interface anomalies, or mimics of wet AMD.,, Some patients respond to treatment, but progress to disciform scarring, retinal pigment epithelial (RPE) tears, massive subretinal hemorrhage, geographic atrophy, or develop tachyphylaxis to anti-VEGF drugs. While there is argument about the timing associated with the de cision of a responder to accept treatment, it would be helpful for AMD patients if the efficacy of anti-VEGF could be determined as early as possible in their treatment, so that non-responders could begin other more appropriate therapy. Evidence showed that most diseases require long-term treatments to maintain the bene ficial effects of the therapy, therefore, the treatment burden is sub stantial for both patients and doctors.,, Hence, it is important to choose the appropriate therapy for an individual patient from the beginning.
Macular telangiectasia type 2 (Mac Tel 2) is an important mimics of wet AMD. In this issue of the Taiwan Journal of Ophthalmology, Wu contributes a comprehensive review of Mac Tel 2. Mac Tel 2, also known as idiopathic perifoveal telangiectasia and juxtafoveo-lar retinal telangiectasis type 2A, is an enigmatic disease of un known etiology that manifests both neurodegenerative and vasculopathic characteristics during the fifth or sixth decades of life. Clinical characteristics include minimally dilated parafoveal capillaries with loss of retinal transparency in the area involved, absence of lipid exudation, right-angled retinal venules, superficial retinal refractile deposits, hyperplasia of the RPE, foveal atrophy, and choroidal neovacularization (CNV). Optical coherent tomogra phy (OCT) images typically demonstrate outer retinal abnormalities and the presence of intraretinal hyporeflective spaces that are usu ally not related with retinal thickening or fluorescein leakage. The typical fluorescein angiographic finding is a deep intraretinal hyperfluorescent staining in the temporal parafoveal area. Over time, this fluorescein hyperfluorescence involves the entire parafo-veal area, but does not extend to the center of the fovea. Long-term prognosis for central vision is poor due to the development of CNV or macular atrophy. Its pathogenesis remains unclear, however, multimodality imaging with fluorescein angiography, spectral domain optical coherence tomography, adaptive optics, confocal blue reflectance, short-wave fundus autofluorescence, OCT angiog-raphy, and clinicopathological correlations implicate Müller cells. Currently there is no known treatment for this condition, unless in the presence of CNV. The eyes of these patients may benefit from anti-VEGF treatment. It is important to choose the right treat ment at the right stage of Mac Tel 2. Otherwise, inaction may in crease the treatment-related risk and burden.
OCT is a non-invasive imaging modality that shows cross-sectional images of the retina, RPE, and choroid. The recently devel oped OCT angiography provides the opportunity to study retinal vasculature without the need for dye injection. OCT angiography offered an even better tool to investigate the anatomical changes associated with Mac Tel 2 and is expected to be a useful guide for treatment. This treatment demonstrates that the earliest vascular changes associated with Mac Tel 2 arise in the outer deep capillary plexus., As the disease progresses, the vascular changes also involve the inner superficial plexus, albeit to a lesser extent than the changes seen in the outer plexus. The vessels appear less densely packed, thinner, and in an abnormal arrangement. The nor mally avascular Henle’s layer and the outer nuclear layers becomes the target of a vascular invasion. Anastomosis between plexi and dragging of vessels temporally are also observed by OCT angiog-raphy. Patients with Mac Tel 2 could be monitored closely to catch the right time for intervention.
Several ocular factors had been reportedly related to AMD prog-ress., In this issue of the Taiwan Journal of Ophthalmology, Lai et al report the relationship of distinct reduced subfoveal choroidal thickness (SFCT) and elongated axial length (AL) with late AMD. A total of 856 eyes of 486 patients (older than 65 years), including 400 eyes at various AMD stages and 456 eyes with no fundus lesions (Controls), were recruited in this case–control study. Their results showed that eyes with thinner SFCT and longer AL showed high odds ratios (ORs) for late AMD, and even higher ORs when both factors were simultaneously present. These findings illustrate the crucial pathophysiological role of these two important ocular factors and arouse our attention to patients with both char acteristics, especially in Asian countries where the prevalence of myopia is disturbingly high. The impacts of these study results on treatment decision making deserve to be further clarified.
In conclusion, the advances in the diagnosis and management of macular disease have made amazing progress in the past decade. Although a variety of trials and studies showed the convincing ef fect of intravitreal pharmacotherapy by anti-VEGF, the optimal treatment regime remained controversial. Improper treatment caused waste of medical resources and increased treatment-related risk for the patients. Current evidence supports the value of individualized treatment for different individuals. We should al ways try to make the correct diagnosis and plan the treatment based on individual factors.
Conflicts of interest: The author declares no conflicts of interest.
| References|| |
Lux A, Llacer H, Heussen F, et al. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol
Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S. Non-re-sponders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br JOphthalmol
Suzuki M, Nagai N, Izumi-Nagai K, et al. Predictive factors for non-response to intravitreal ranibuzumab treatment in age-related macular degeneration. Br J Ophthalmol
Schaal S, Kaplan H, Tezel T. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degenera tion? Ophthalmology
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology
IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, et al. Ranibi-zumab versus bevacizumab to treat neovascular age-related macular degener ation: one-year findings from the IVAN randomized trial. Ophthalmology
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injec tion for neovascular age-related macular degeneration: ninety-six-week re sults of the VIEW studies. Ophthalmology
Wu L. When is macular edema not macular edema? An update on macular tel-angiectasia type 2. Taiwan JOphthalmol
Wu L, Evans T, Arevalo JF. Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2). Surv Ophthalmol
Thorell MR, Zhang Q, Huang Y, et al. Swept-source OCT angiography of macular telangiectasia type 2. Ophthalmic Surg Lasers Imaging Retina
Spaide RF, Klancnik Jr JM, Cooney MJ. Retinal vascular layers in macular telan-giectasia type 2 imaged by optical coherence tomographic angiography. JAMA Ophthalmol
Wang CP, Lai CH, Huang JC, et al. Axial length and subfoveal choroidal thickness in individuals with age-related macular degeneration. Taiwan J Ophthalmol